Special clinical interests in Breast, Urology, Stereotactic Radiation Therapy, Brachytherapy and Rectal Spacers
Michael is an Associate Professor and Radiation Oncologist specialising in breast, lower gastrointestinal and prostate cancers. He has over 21 years of experience as a radiation oncologist. His particular area of expertise is in prostate brachytherapy (which includes both Iodine-125 low dose rate (LDR) permanent seed implants and Iridium-192 high dose rate (HDR) temporary implants) and rectal spacers for prostate cancer which he introduced in 2013. He has now completed more than 1000 prostate cancer implants and more than 500 rectal spacer procedures. In addition, he has a major interest in the use of preoperative radiotherapy for locally advanced breast cancers prior to breast reconstructions and also for early disease where he is leading innovative partial breast treatments.
Michael completed his MBBS at Monash University in 1991 graduating with Honours. He received his Fellowship of the Royal Australian and New Zealand College of Radiologists (FRANZCR) in 1999. This was followed by two years as a research fellow at the DNA Research Laboratory at the Peter MacCallum Cancer Centre. He was both an NHMRC Scholar and Sir Edward ‘Weary’ Dunlop Research Fellow. He has also completed his doctorate (D Med Sc) with the University of Melbourne via the Department of Surgery in the field of Urology. He commenced as a consultant radiation oncologist in 2000 joining Genesis Care Victoria. He consults at the Ringwood and Frankston Genesis Care Radiation Oncology Centres. He is both an honorary radiation oncologist Maroondah Hospital (Eastern Health) and VMO at the Olivia Newton John Cancer and Wellness Centre where he is the breast cancer lead.
Michael is a member of the American Society of Therapeutic Radiology and Oncology, European Society of Radiation Oncology, Australasian Society of Breast Diseases, American Brachytherapy Society and Australasian Brachytherapy Group.
He has presented and published (>100 articles/abstracts) widely on breast and prostate cancers in radiation oncology. He is involved in multi-centre clinical trials and has completed a number of investigator initiated trials in prostate and breast cancer with external and industry grants totalling <$1M. He regularly attends international conferences, and keeps abreast of all latest developments in radiation oncology, particularly in his areas of interest.